Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
A new configuration of the I-SPY Platform, named I-SPY2.2, introduces sequential multiple-assignment randomization to improve matching of therapy …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
New oral vaccine succeeds against multiple cholera strains offering promise for broad use in endemic regions
A new antibody-drug conjugate brings hope for patients with lung cancer who have few options
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
The World Health Organization galvanized global efforts to make clinical trials faster, more inclusive, and deeply rooted in …
Targeted treatment approach shows potential to reshape how antidepressants are prescribed
Already a subscriber? Log in